The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder ...

AstraZeneca (NASDAQ:AZN) has announced positive results from a late-stage trial testing Imfinzi (durvalumab) combined with ...

B ERLIN -- Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly ...

Durvalumab addition to BCG therapy significantly improved DFS in BCG-naive, high-risk NMIBC patients, achieving a 32% reduction in DFS event risk. The combination therapy was well-tolerated, with ...

Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet.

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ Treatment with cretostimogene monotherapy continues ...

ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, helping eliminate cancer Already approved in the ...

There’s a new twist in the fight against bladder cancer — and it’s delivering game-changing results. In a recent clinical trial, a pretzel-shaped device that slowly releases chemotherapy drugs ...

The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, ...

Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter. The Food and Drug Administration (FDA) has approved Inlexzo ™ ...

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...